#ProstateCancerAwarenessMonth is recognized every September. Outside of skin cancer, #prostatecancer is the most common cancer in men. According to the American Cancer Society, in 2024, roughly 299,010 new cases of prostate cancer will occur in the United States. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime. In recent decades, many exciting, innovative treatment options for prostate cancer are becoming more readily available to patients. New technologies are allowing for more precise therapies than traditional methods. After receiving an early-stage prostate cancer diagnosis, Brian Belcastro was initially told he would need daily radiation treatments for nine weeks. Brian sought a second opinion with Dr. Luis Carrascosa, a board-certified radiation oncologist at Florida Cancer Specialists & Research Institute. After reviewing Brian’s diagnosis and discussing his desire to maintain his normal, active lifestyle, Dr. Carrascosa informed Brian that he could be treated in five sessions using an exact and advanced form of radiation known as stereotactic body radiation therapy (SBRT). Today, more than one year after completing his treatment without side effects, Brian is disease-free and enjoying life. Brian is among the growing number of patients now receiving short-term radiation therapy for many forms of cancer with positive results. To learn more about our comprehensive radiation oncology services for prostate cancer and other cancer types, visit https://lnkd.in/eSXVSJP8.
Florida Cancer Specialists & Research Institute的动态
最相关的动态
-
Let’s nourish our patients! Only 50% of malnourished patients receive appropriate treatment. Let’s raise awareness during #ASPENMAW24! nutritioncare.org/MAW-24 FCS is proud to partner with the American Society for Parenteral & Enteral Nutrition (ASPEN) as an ambassador for Malnutrition Awareness Week.
-
-
Florida Cancer Specialists & Research Institute is intentional in bringing world-class oncology and hematology care to patients. To make this possible, our physicians, experts in administering the latest and most advanced treatments for cancer, are available within the communities where our patients live. As our footprint expands into new markets, we welcome such talented individuals to explore a medical career at FCS. Our physicians have access to a network of 250+ physician peers with resources such as clinical trials, advanced therapies and innovative testing and technology at their fingertips. Consider one of these exciting opportunities today: https://lnkd.in/eYgrmi3m #oncologist #hematologist #radiologist #radiationoncologist #oncology #hematology #radiationoncology #clinicaltrials
-
-
The safety and well-being of our patients and employees is our highest priority. Our Englewood location is temporarily closed due to some unexpected but necessary repairs. Our teams are working diligently to minimize any disruptions in patient care during this time. We expect the office to be closed beginning Thursday, September 12, 2024, and to last for at least two weeks. Patients with existing appointments are being contacted by FCS team members and will have their appointments rescheduled to the following FCS locations until the Englewood office reopens: North Port Cancer Center 1390 Grand Venture Dr, North Port, FL 34286-2309 Office: (941) 257-2280 Venice Healthpark 836 Sunset Lake Blvd, Ste 101, Venice, FL 34292-7555 Office: (941) 408-0500 Venice Island 901 S Tamiami Trail, Venice, FL 34285-3668 Office: (941) 484-3531 At this time, patients of Englewood may direct specific questions to the Englewood office (941) 460-1300, as calls will still be answered at that number. If closed, our answering service will assist you with any non-medical emergencies. In case of a medical emergency, please dial 911. Thank you all for your understanding. All other FCS offices will be open as scheduled. The latest updates can also be found here, on our Facebook, Instagram and LinkedIn social media pages, our website at https://lnkd.in/eRUZqivc or by calling the Patient Emergency Notification Hotline: (866) 385-1430.
-
-
Groundbreaking research conducted at Florida Cancer Specialists & Research Institute continues to make a global impact as six FCS physicians will present their findings as first authors and/or co-authors of 20 cancer research studies at the ESMO - European Society for Medical Oncology Congress 2024 in Barcelona, Spain over the next few days. The abstracts accepted consist of early and late-phase research conducted at many of our 30 late-phase locations or three drug development units in Florida. Learn more here: https://lnkd.in/eUgcuZyA
-
-
FCS physicians, clinicians and leaders will participate as expert panelists at the Patient-Centered Oncology Care? (PCOC) conference presented by AJMC - The American Journal of Managed Care this week in Nashville. The theme, Innovations in Cancer Care: Tales from the Front Line, sets the stage for discussions around relevant issues in the delivery of cancer care in community settings ranging from pharmacy, to clinical pathways and holistic value-based care models. Learn more here: https://lnkd.in/ebWhDcgy Maen Hussein Gustavo Fonseca Paul Chadwick Josh Eaves Kiana Mehring, MBA Chris Elder, PharmD, BCOP
-
-
Every year, we honor and remember those who gave their lives to save others during the attacks on September 11, 2001. Their heroism and bravery will never be forgotten. On #PatriotsDay, our thoughts are with those we lost in these tragic events. Together, we are strong and resilient. ????
-
September is Leukemia & Lymphoma Awareness Month. #Leukemia and #lymphoma are different types of #bloodcancer. Leukemia occurs when high levels of abnormal white blood cells (WBCs) develop in the bone marrow. Lymphoma is a type of cancer that affects the lymphatic system and specific WBCs called lymphocytes, which are essential cells in our immune function. According to the National Cancer Institute (NCI), about 62,770 new cases of leukemia will occur in the United States in 2024. The American Cancer Society estimates that 80,620 people will be diagnosed with non-Hodgkin lymphoma, the most common type of lymphoma that is also one of the most common cancer types in the U.S. — accounting for roughly 4% of all cancer cases. Hodgkin lymphoma, a lesser common form of lymphoma, is expected to have 8,570 new cases in 2024. Jim Marshall, a Tampa Bay businessman, was diagnosed with Hodgkin lymphoma in the fall of 2005 after seeking medical advice from suddenly feeling tired and run down often. A patient of Florida Cancer Specialists & Research Institute (FCS) Medical Oncologist/Hematologist Dr. Idelfia Marte, he successfully completed treatment in 2006. Almost 20 years cancer-free, Jim cannot thank FCS enough for the outstanding care he received. Now a member of the American Cancer Society's CEOs Against Cancer - Florida Chapter, Jim is a huge proponent of encouraging others to #getscreened. #leukemiaawareness #lymphomaawareness
-
?? Hear from our patients ?? At Florida Cancer Specialists & Research Institute, our patients are at the heart of everything we do. From the moment you walk through our clinic doors, regardless of the location, our dedicated teams are here to support you with the highest level of care, compassion and service. We are pleased to share a recent review featuring FCS Medical Oncologist/Hematologist Dr. Blessy Jacob. Dr. Jacob leads an expert team that provides the most advanced, comprehensive oncology and hematology care to patients in Sarasota County. To learn more, visit https://lnkd.in/e7jmVsG7. ?? Share your story! How has FCS made a difference in your journey? #patientvoices #caregivervoices #patientcare #oncologycare #communityoncology
-
Next-generation sequencing (NGS) continues to be a crucial contributor to advancing care for our patients. We are proud to partner with NCODA and highlight how our teams are utilizing NGS testing to steer treatment and optimize outcomes. Austin Cox Maen Hussein
Advances in multiple myeloma (MM) treatment include effective minimal residual disease (MRD) testing. The clonoSEQ assay, the only FDA-cleared MRD test for MM, uses next-generation sequencing (NGS) to monitor treatment success. NCODA’s PQI on clonoSEQ? Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma PQI highlights MRD testing’s crucial role, especially during maintenance phases, ensuring effective and less intensive therapy. Collaborating with NCODA, Florida Cancer Specialists & Research Institute and Rocky Mountain Cancer Centers share their insights on utilizing this PQI to streamline best practices and enhance care for MM patients.? Read more:?https://bit.ly/4ghzIEC
